Quick Answer
Elicio Therapeutics, Inc. reported Total Revenue of $2.30 million for the year ending 2022.
- Elicio Therapeutics, Inc. showed a decrease of -91.9% in Total Revenue from 2021 to 2022.
- This data is from Elicio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2023.
- XBRL data for this metric is available from 2020 to 2022 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $865.0 thousand | Q2 2020: $729.0 thousand | Q3 2020: $827.0 thousand | Q1 2021: $371.0 thousand | Q2 2021: $540.0 thousand | Q3 2021: $1.46 million | Q1 2022: $1.65 million | Q2 2022: $653.0 thousand | Q3 2022: $0.00 | Q1 2023: $0.00.
- Over the full 3 years of available data (2020 to 2022), Elicio Therapeutics, Inc.'s Total Revenue has declined by 20.1%.
- Historical annual values: Fiscal year 2022: $2.30 million | Fiscal year 2021: $28.31 million | Fiscal year 2020: $2.88 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: